This week's headlines include: Trump says drug companies to announce 'massive' price cuts soon, FDA puts Vertex, CRISPR sickle cell trial on hold, Trump signs 'right to try' drug bill, Research Suggests How A Common, Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable, Who gets credit for CRISPR? Prestigious award singles out three, and leaves out a notable scientist, and Trio of genes supercharged human brain evolution.
GMP requirements touch every single use assembly used in clinical studies to commercial manufacturing. The drug product produced in clinical studies are given to patients. GMP practices followed in producing the single use assemblies will ensure that there is no risk to patients in clinical trials and future commercial products.
IF WE CAN"T PROVE GMP WHAT HAPPENS?
The BioFactory Competence Center (BCC) in Fribourg, Switzerland has partnered with Pall Biotech to offer a continuous downstream processing training course from 3rd – 5th July 2018. Attendees will learn about the different technologies available for continuous processing steps including cell separation, filtration and chromatography. The three day course is focussed on practical hands-on work in the laboratory with small class sizes. Further information can be found at http://www.bcc.ch/continuous-downstream-processing.html.
Opened in 2016, the BCC is a non-profit educational facility dedicated to advancing the biopharmaceutical industry through educational sessions and real-time support. Pall Biotech is a leading manufacturer of continuous bioprocessing equipment.